The COVID-19 vaccine is really safe for the overwhelming majority of individuals. On a few very rare events, there have actually been some cases of blood clotting in the brain. This kind of blood clot is called cerebral venous thrombosis (CVT) and it can lead to strokes and even death.Researchers at University College London have performed a study of people with CVT following vaccination, to provide a clearer guide for clinicians trying to diagnose and treat such patients.The research study, which is released in The Lancet, is the most detailed account of the attributes of CVT, when it is caused by the novel condition vaccine-induced immune thrombotic thrombocytopenia (VITT). Researchers from the John Radcliffe Hospital in Oxford took a look at the information of 70 clients with VITT-associated CVT following vaccination.They compared these patients to 25 patients with CVT however without the proof of VITT.Their study provides 3 concepts of treatment developed up until now by the Expert Hematology Panel.These include making use of non-heparin-based anticoagulation, administering treatments to attempt to decrease the level of the abnormal antibody that is implicated in this condition and preventing the technique of trying to bring the platelet count back up to typical levels by providing platelet transfusions.Researchers saw that patients who were provided intravenous immunoglobulin, a treatment in which the body is flooded with regular antibodies to try to lower the impacts of the abnormal one, was the most effective.These patients are able to live an independent life instead of depending upon carers or household to care for them.READ MORE: UK to axe landline phones in digital shake-up triggering fears for elderly and vulnerableBut researchers caution that though this kind of seem to be related to better outcomes, one need to exercise caution versus reading too much into the findings of the observational study.They desire to now progress to a randomised scientific trial to confirm their results.It comes after a current population-based study commissioned by the European Medicine Agency (EMA) discovered that blood-clotting events after receiving the AstraZeneca vaccine were the very same or less regular than for those who received the Pfizer mRNA vaccine.In March, concerns were been raised over blood-clotting events connected with the AstraZeneca vaccine.One month later on, the safety committee of the EMA concluded that there may be a link between the AstraZeneca vaccine and extremely unusual cases of unusual blood clots.DONT MISS. EU shamed as forests destroyed to make green energy [REPORT] Never mind China the climate change fight begins at home [COMMENT] Rishi Sunak leads battle versus PMs extraordinary green target [INSIGHT] These uncommon blood clots happened in veins in the brain, the abdomen and in arteries, in mix with low levels of blood platelets.The announcement came on the heel of lots of European nations, including Germany and France, suspending their usage of AstraZeneca.French President Emmanuel Macron freely denigrated the AstraZeneca vaccine in January, calling it “quasi-ineffective”. The repercussions are said to have had a devastating effect on the European and the global vaccination project.